DR. WILLIAM MAIXNER, DDS, PHD
Dentist in Chapel Hill, NC
License number
North Carolina 0018
Category
Dentist
Type
General Practice
Address
Address
101 Brauer Hall Cb #7450, Chapel Hill, NC 27599
Phone
(919) 966-1221
Organization information
See more information about WILLIAM MAIXNER at bizstanding.comWilliam Maixner DDS,PHD
101 Brauer Hall Cb, Chapel Hill, NC 27599
Industry:
Dentists
Phone:
(919) 966-1221 (Phone)
William Maixner
Professional information
Dr. William Maixner, Chapel Hill NC - DDS (Doctor of Dental Surgery)
Specialties:
Dentistry
Address:
101 Brauer Hall Cb STE 7450, Chapel Hill 27599
(919) 966-1221 (Phone)
(919) 966-1221 (Phone)
Languages:
English
Education:
Medical School
Graduates of Institutions Not Listed As Medical Schools
Graduates of Institutions Not Listed As Medical Schools
Compositions And Methods For The Treatment Of Somatosensory Disorders
US Patent:
2013022, Aug 29, 2013
Filed:
Mar 14, 2013
Appl. No.:
13/829327
Inventors:
William Maixner - Chapel Hill NC, US
Assignee:
ALGYNOMICS INC. - Chapel Hill NC
International Classification:
A61K 31/138, A61K 45/06
US Classification:
514652
Abstract:
A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.
Methods And Materials For Determining Pain Sensitivity And Predicting And Treating Related Disorders
US Patent:
2010013, May 27, 2010
Filed:
Jul 25, 2005
Appl. No.:
11/632141
Inventors:
Luda B. Diatchenko - Chapel Hill NC, US
William Maixner - Chapel Hill NC, US
Gary Slade - South Australia, AU
Andrea Gail Neeley - Durham NC, US
William Maixner - Chapel Hill NC, US
Gary Slade - South Australia, AU
Andrea Gail Neeley - Durham NC, US
International Classification:
A01K 67/00, C12Q 1/68, A61K 31/415, A61K 31/135, A61K 31/438
US Classification:
800 9, 435 6, 514401, 514651, 514278
Abstract:
Methods of treating somatosensory disorders and modulating production of proinflammatory cytokines by administering to a subject an effective amount of a COMT modulator, ADRB2 modulator, ADRB3 modulator or combinations thereof are provided. Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided. Methods of determining pain responses or pain perception and predicting susceptibility of a subject to develop related disorders, such as somatosensory disorders and somatization, by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided.
Compositions And Methods For The Treatment Of Somatosensory Disorders
US Patent:
2011024, Oct 6, 2011
Filed:
Mar 30, 2011
Appl. No.:
13/076386
Inventors:
Luda Diatchenko - Chapel Hill NC, US
William Maixner - Chapel Hill NC, US
William Maixner - Chapel Hill NC, US
Assignee:
ALGYNOMICS INC. - Chapel Hill NC
International Classification:
A61K 31/138, A61K 31/485, A61K 31/167, A61K 31/135, A61K 31/4468, A61K 31/60, A61K 31/635, A61K 31/421, A61K 31/55, A61K 31/5513, A61K 31/57, A61P 29/00, A61P 25/06, A61P 1/00, A61P 25/00, A61P 19/02, A61P 9/10, C12Q 1/02
US Classification:
514158, 514652, 514282, 514629, 514648, 514329, 514289, 514295, 514162, 514374, 514217, 514221, 514171, 435 29
Abstract:
A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.
Methods And Materials For Determining Pain Sensitivity And Predicting And Treating Related Disorders
US Patent:
2013024, Sep 19, 2013
Filed:
Sep 21, 2012
Appl. No.:
13/624608
Inventors:
William Maixner - Chapel Hill NC, US
Gary D. Slade - Chapel Hill NC, US
Andrea Gail Neely - Durham NC, US
Gary D. Slade - Chapel Hill NC, US
Andrea Gail Neely - Durham NC, US
Assignee:
University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
Methods of treating somatosensory disorders and modulating production of proinflammatory cytokines by administering to a subject an effective amount of a COMT modulator, ADRB2 modulator, ADRB3 modulator or combinations thereof are provided. Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided. Methods of determining pain responses or pain perception and predicting susceptibility of a subject to develop related disorders, such as somatosensory disorders and somatization, by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided.
Identification Of Genetic Polymorphic Variants Associated With Somatosensory Disorders And Methods Of Using The Same
US Patent:
2009025, Oct 8, 2009
Filed:
Nov 29, 2006
Appl. No.:
12/085785
Inventors:
Luda Diatchenko - Chapel Hill NC, US
William Maixner - Chapel Hill NC, US
William Maixner - Chapel Hill NC, US
International Classification:
C40B 30/04, C40B 40/06, G06F 19/00
US Classification:
506 9, 506 16, 702 19
Abstract:
Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with or without determination of psychosocial and/or neurological assessments of the subject are provided. Methods of predicting susceptibility of a subject to develop somatosensory disorders by determining a genotype of the subject with or without determination of psychosocial and/or neurological assessments of the subject are further provided.